Core Viewpoint - Nuvectis Pharma, Inc. (NVCT) has experienced a significant downtrend, losing 52.8% over the past two weeks, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest and analyst support for earnings estimates [1] Group 1: Technical Analysis - The formation of a hammer chart pattern indicates a possible bottoming out of the stock, suggesting that selling pressure may be subsiding [1] - A hammer pattern typically occurs during a downtrend, where the stock opens lower, makes a new low, but then closes near or above the opening price, signaling a potential loss of control by bears [2] - Hammer candles can appear on various timeframes and are used by both short-term and long-term investors, although they should be combined with other bullish indicators for confirmation [2] Group 2: Fundamental Analysis - Recent upward revisions in earnings estimates for NVCT serve as a bullish indicator, with the consensus EPS estimate increasing by 3.8% over the last 30 days, reflecting analysts' confidence in the company's earnings potential [3] - NVCT holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [3] - The Zacks Rank is a reliable timing indicator, suggesting that NVCT's prospects are improving, further supporting the case for a potential turnaround [3]

Core Viewpoint - Nuvectis Pharma, Inc. reported data from a Phase 1b study of NXP800 for treating platinum-resistant ARID1a-mutated ovarian cancer, leading to a significant decline in stock price. Group 1: Study Details - The Phase 1b study evaluated three dosing regimens in twelve patients, with four patients on a once-per-day schedule of either 75 mg or 50 mg [1] - Eight additional patients were treated with 50 mg/day on an intermittent schedule of five days on and two days off to reduce thrombocytopenia risk [2] - All patients had previously failed at least two lines of systemic chemotherapy, including one platinum-based regimen, with most also having failed bevacizumab treatment [2] Group 2: Efficacy and Safety - Among eleven efficacy-evaluable patients, antitumor activity was noted, with one unconfirmed partial response and six patients showing stable disease [3] - In the initial safety evaluation, three out of four patients experienced Grade 4 thrombocytopenia, while the intermittent dosing schedule resulted in a maximum of Grade 2 thrombocytopenia in one patient [3][4] - Common treatment-emergent adverse events included nausea, fatigue, vomiting, diarrhea, and constipation, primarily Grade 1-2 [4] Group 3: Future Plans and Designations - The CEO indicated a need to increase dose intensity for better efficacy, with plans to enroll 10-12 additional patients at 75 mg/day on an intermittent schedule [5] - The NXP800 program received FDA Fast Track Designation and Orphan Drug Designation for specific ovarian cancers [5] Group 4: Market Reaction - Following the report, NVCT stock fell by 43.20%, trading at $6.05 [6]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance - Nuvectis Pharma, Inc. (NVCT) has shown a solid price increase of 51.9% over the past 12 weeks, indicating strong investor interest [4]. - Over the last four weeks, NVCT's price has increased by 69.2%, suggesting that the upward trend is still intact [5]. - NVCT is currently trading at 82.1% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - NVCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like NVCT that are on an uptrend supported by strong fundamentals [3]. - Investors are encouraged to explore over 45 Zacks Premium Screens tailored to different investing styles to find potential winning stocks [8].

Core Viewpoint - Nuvectis Pharma, Inc. (NVCT) has shown a significant price increase of 34.3% over the past four weeks, with a mean price target of $22 indicating a potential upside of 169.9% from the current trading price of $8.15 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $2.65, where the lowest estimate of $20 suggests a 145.4% increase, and the highest estimate of $25 indicates a potential surge of 206.8% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement direction and magnitude, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Sentiment - There is increasing optimism among analysts about NVCT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with near-term stock price movements [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.6%, with one estimate moving higher and no negative revisions [10] Zacks Rank and Investment Potential - NVCT currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [11]

Financial Performance - Nuvectis Pharma reported a net loss of $4.2 million for Q3 2024, a decrease from $5.9 million in Q3 2023, representing a 29.6% improvement year-over-year[4]. - The basic and diluted net loss per common share outstanding was $0.24 for Q3 2024, compared to $0.37 for Q3 2023[11]. Cash and Investments - Cash, cash equivalents, and short-term investments decreased to $17.2 million as of September 30, 2024, down from $19.1 million as of December 31, 2023, a decline of approximately 10.0%[3]. - Nuvectis expects its current cash position to support important milestones for clinical programs and provide working capital well into 2026[2]. Expenses - Research and development expenses were $2.8 million for Q3 2024, down from $4.5 million in Q3 2023, indicating a reduction of 37.2%[5]. - General and administrative expenses decreased to $1.5 million in Q3 2024 from $1.7 million in Q3 2023, a decline of 12.0%[5]. Clinical Development - The company has completed 4 cohorts in the NXP900 Phase 1a dose escalation study with no dose limiting toxicities reported[2]. - NXP800 has received Orphan Drug Designation from the FDA for treating ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers[2]. - The company anticipates a clinical data update from the NXP800 Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer within the month[2]. Stockholders' Equity - The total stockholders' equity decreased to $10.99 million as of September 30, 2024, from $12.20 million as of December 31, 2023[10].

Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancersNXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on t ...

Financial Performance - For the three months ended June 30, 2024, the operating loss was $4,643,000, compared to an operating loss of $5,772,000 for the same period in 2023, representing a 19.6% improvement[13]. - The net loss for the three months ended June 30, 2024, was $4,428,000, compared to a net loss of $5,708,000 for the same period in 2023, indicating a 22.4% reduction in losses[13]. - The company reported a net loss of $8.6 million for the six months ended June 30, 2024, compared to a net loss of $9.8 million for the same period in 2023, representing a 12% improvement[21]. - The net loss for the six months ended June 30, 2024, was $8,599,000, a 12% improvement from a net loss of $9,757,000 for the same period in 2023[21]. - The basic net loss attributable to common stockholders for the three months ended June 30, 2024, was $4.4 million, resulting in a basic net loss per share of $0.26[48]. - Basic net loss per common share for the three months ended June 30, 2024, was $0.26, a decrease from $0.38 in the same period of 2023, indicating a 31.6% reduction in loss per share[48]. - The basic net loss per share for the six months ended June 30, 2024, was $0.51, down from $0.65 in the same period of 2023, showing a 21.5% improvement[48]. - The company recognized a total net loss of $8.599 million for the six months ended June 30, 2024, compared to $9.757 million for the same period in 2023, reflecting a 11.9% reduction[48]. Expenses and Liabilities - Research and development expenses for the six months ended June 30, 2024, were $5,603,000, down from $6,629,000 in the same period of 2023, a decrease of 15.4%[13]. - For the three months ended June 30, 2024, the company recognized $0.5 million in general and administrative expenses and $0.7 million in research and development expenses[46]. - Research and development expenses for the three months ended June 30, 2024, were $2,943,000, a decrease of 31% compared to $4,262,000 for the same period in 2023[13]. - Total current liabilities were $5,770,000, a decrease from $6,984,000 as of December 31, 2023, reflecting a 17.4% reduction[13]. - The total stockholders' equity as of June 30, 2024, was $12,528,000, a decrease from $20,332,000 as of June 30, 2023, indicating a decline of 38%[19]. Capital and Funding - The company will require substantial additional capital to finance its operations and achieve its goals[6]. - The company will need to raise additional capital to complete clinical trials for its product candidates, with no assurance of securing sufficient financing[25]. - The company raised approximately $6.6 million through the sale of 749,338 common shares under its At-the-Market Program during the six months ended June 30, 2024, at an average selling price of $8.78 per share[24]. - The company sold 246,691 common shares under its At-the-Market Program for gross proceeds of approximately $1.7 million during the three months ended June 30, 2024[23]. - As of June 30, 2024, approximately $28.1 million of securities remain available under the At-the-Market Program[40]. - The company has not generated any revenue to date and expects to incur continued losses for the foreseeable future[6]. Workforce and Operations - The company currently has 13 full-time employees and plans to grow its workforce to support its operations[9]. - The company has incurred net operating losses since its inception, highlighting the need for strategic financial planning[23]. - The company has a limited operating history and has only initiated a limited number of clinical trials, which may affect investor evaluation of its business[5]. - The company is dependent on the success of its product candidates, NXP800 and NXP900, for future revenue generation[7]. - The company is dependent on the success of its product candidates, NXP800 and NXP900, which are currently in clinical trials[7]. Stock Options and Awards - As of June 30, 2024, the company had 348,281 stock options outstanding with a weighted average exercise price of $4.59 and an intrinsic value of $606,000[41]. - The company granted 580,527 restricted stock awards (RSAs) during the six months ended June 30, 2024, with a weighted average grant fair value of $8.09[42]. - Total unrecognized compensation cost related to RSAs as of June 30, 2024, was $4.5 million, expected to be recognized over a weighted average period of 1.34 years[43]. - The total share compensation expense for the three months ended June 30, 2024, was $1.2 million, up from $1.0 million in the same period of 2023, marking a 20% increase[46]. - The company excluded 1,588,313 unvested RSAs from the diluted net loss per common share calculation for June 2024, compared to 1,093,613 for June 2023, indicating a significant increase in potentially dilutive securities[50]. Cash Flow and Financial Position - Cash and cash equivalents decreased to $18.1 million as of June 30, 2024, down from $24.6 million at the end of the same period in 2023[21]. - The company has not generated positive cash flows from operations and relies primarily on the issuance and sale of common stock to fund operations[23]. - Management believes that existing cash and cash equivalents will fund planned operations for at least 12 months following the issuance date of the financial statements[24]. - The company experienced a net cash used in operating activities of $7,378,000 for the six months ended June 30, 2024, compared to $8,860,000 for the same period in 2023, showing a 17% reduction[21].

Financial Performance - Cash and cash equivalents decreased to $18.1 million as of June 30, 2024, down from $19.5 million as of March 31, 2024, a decrease of $1.4 million[3] - The net loss for Q2 2024 was $4.4 million, a decrease of $1.4 million compared to a net loss of $5.8 million in Q2 2023[3] - Research and development expenses were $2.9 million for Q2 2024, down from $4.3 million in Q2 2023, representing a decrease of approximately 32.6%[3] - General and administrative expenses increased to $1.7 million in Q2 2024 from $1.5 million in Q2 2023, an increase of approximately 13.3%[4] - Interest income rose to $0.2 million in Q2 2024, compared to $0.1 million in Q2 2023, an increase of 100%[4] Clinical Trials and Developments - The Phase 1b clinical trial for NXP800 is ongoing with patient enrollment at approximately 15 clinical sites in the U.S. and U.K.[2] - The company plans to provide updates on the NXP800 and NXP900 trials by the end of 2024 and during the fall of 2024, respectively[2] - NXP800 has received Fast Track Designation from the FDA for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma[5] Liabilities and Equity - Total current liabilities were $5.77 million as of June 30, 2024, down from $6.98 million as of March 31, 2024[7] - Total stockholders' equity increased to $12.53 million as of June 30, 2024, compared to $12.20 million as of December 31, 2023[9]

FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the second quarter 2024 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "During the second quart ...

Group 1 - Nuvectis Pharma, Inc. (NVCT) closed at $6.68, with a 2.6% gain over the past four weeks, and has a mean price target of $22, indicating a 229.3% upside potential [1] - The mean estimate includes three short-term price targets with a standard deviation of $2.65, where the lowest estimate of $20 suggests a 199.4% increase, and the highest estimate of $25 indicates a 274.3% increase [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [10][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 15.3% over the last 30 days, with two estimates moving higher and no negative revisions [11] - NVCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [12] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does suggest a positive direction for price movement [12]